본문 바로가기
KERD
논문KCI 등재

Recent Developments in the Therapeutic Landscape of Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

이대원|이경훈|임석아|Eunice Yoojin Lee
대한암학회 (Korean Cancer Association)|2023.10|Cancer Research and Treatment|제55권 제4호|pp. 1065-1076|DOI 10.4143/crt.2023.846

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Breast neoplasmsEndocrine therapyHormone receptor positiveCDK4/6 inhibitor
주제분류의학일반

초록

Hormone receptor–positive (HR+) disease is the most frequently diagnosed subtype of breast cancer. Among tumor subtypes, natural course of HR+ breast cancer is indolent with favorable prognosis compared to other subtypes such as human epidermal growth factor protein 2–positive disease and triple-negative disease. HR+ tumors are dependent on steroid hormone signaling and endocrine therapy is the main treatment option. Recently, the discovery of cyclin-dependent kinase 4/6 inhibitors and their synergistic effects with endocrine therapy has dramatically improved treatment outcome of advanced HR+ breast cancer. The demonstrated efficacy of additional nonhormonal agents, such as targeted therapy against mammalian target of rapamycin and phosphatidylinositol 3-kinase signaling, poly(ADP-ribose) polymerase inhibitors, antibody-drug conjugates, and immunotherapeutic agents have further expanded the available therapeutic options. This article reviews the latest advancements in the treatment of HR+ breast cancer, and in doing so discusses not only the development of currently available treatment regimens but also emerging therapies that invite future research opportunities in the field.

Abstract

Hormone receptor–positive (HR+) disease is the most frequently diagnosed subtype of breast cancer. Among tumor subtypes, natural course of HR+ breast cancer is indolent with favorable prognosis compared to other subtypes such as human epidermal growth factor protein 2–positive disease and triple-negative disease. HR+ tumors are dependent on steroid hormone signaling and endocrine therapy is the main treatment option. Recently, the discovery of cyclin-dependent kinase 4/6 inhibitors and their synergistic effects with endocrine therapy has dramatically improved treatment outcome of advanced HR+ breast cancer. The demonstrated efficacy of additional nonhormonal agents, such as targeted therapy against mammalian target of rapamycin and phosphatidylinositol 3-kinase signaling, poly(ADP-ribose) polymerase inhibitors, antibody-drug conjugates, and immunotherapeutic agents have further expanded the available therapeutic options. This article reviews the latest advancements in the treatment of HR+ breast cancer, and in doing so discusses not only the development of currently available treatment regimens but also emerging therapies that invite future research opportunities in the field.

참고문헌 (81)

  1. Sung H, "Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
  2. Sorlie T, "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications", Proc Natl Acad Sci U S A, 98, pp.10869~10874 (2001)
  3. Goldhirsch A, "Strategies for subtypes : dealing with the diversity of breast cancer : highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011", Ann Oncol, 22, pp.1736~1747 (2011)
  4. Zhang MH, "Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials(Review)", Biomed Rep, 2, pp.41~52 (2014)
  5. Huppert LA, "Systemic therapy for hormone receptor-positive", human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer, 2023, pp.73, 480~515
  6. Patel HK, "Selective estrogen receptor modulators(SERMs)and selective estrogen receptor degraders(SERDs)in cancer treatment", Pharmacol Ther, 186, pp.1~24 (2018)
  7. Miller WR, "Aromatase inhibitors : are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?", Oncologist, 13, pp.829~837 (2008)
  8. Gennari A, "ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer", Ann Oncol, 32, pp.1475~1495 (2021)
  9. Scott SC, "Mechanisms of therapeutic CDK4", 6 inhibition in breast cancer, 2017, pp.44, 385~394
  10. Finn RS, "PD 0332991, a selective cyclin D kinase 4", 6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro, 2009, pp.11, R77~
  11. Finn RS, "The cyclin-dependent kinase 4", 6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer(PALOMA-1, Lancet Oncol, pp.2015, 16[DOI]
  12. Finn RS, "Palbociclib and letrozole in advanced breast cancer", N Engl J Med, 375, pp.1925~1936 (2016)
  13. Hortobagyi GN, "Ribociclib as first-line therapy for HR-positive, advanced breast cancer", N Engl J Med, 375, pp.1738~1748 (2016)
  14. Hortobagyi GN, "Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer", Ann Oncol, 29, pp.1541~1547 (2018)
  15. Im SA, "Overall survival with ribociclib plus endocrine therapy in breast cancer", N Engl J Med, 381, pp.307~316 (2019)
  16. Lu YS, "Updated Overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre-and perimenopausal patients with HR+", HER2-advanced breast cancer in MONALEESA-7 : a phase III randomized clinical trial, 2022, pp.28, 851~859
  17. Johnston S, "MONARCH 3 final PFS : a randomized study of abemaciclib as initial therapy for advanced breast cancer", NPJ Breast Cancer, 5, pp.5~ (2019)
  18. Goetz MP, "LBA15 MONARCH 3 : interim overall survival(OS)results of abemaciclib plus a nonsteroidal aromatase inhibitor(NSAI)in patients(pts)with HR+, HER2-advanced breast cancer(ABC)", Ann Oncol, 33, pp.S1384~ (2022)
  19. Slamon DJ, "Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial : updated overall survival", Ann Oncol, 32, pp.1015~1024 (2021)
  20. Turner NC, "Palbociclib in hormone-receptor-positive advanced breast cancer", N Engl J Med, 373, pp.209~219 (2015)
  21. Sledge GW Jr, "MONARCH 2 : abemaciclib in combination with fulvestrant in women with HR+", HER2-advanced breast cancer who had progressed while receiving endocrine therapy, 2017, pp.35, 2875~2884
  22. Tripathy D, "Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer(MONALEESA-7) : a randomised phase 3 trial", Lancet Oncol, 19, pp.904~915 (2018)
  23. Cristofanilli M, "Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy(PALOMA-3) : final analysis of the multicentre, double-blind, phase 3 randomised controlled trial", Lancet Oncol, 17, pp.425~439 (2016)
  24. Finn RS, "Overall survival(OS)with first-line palbociclib plus letrozole(PAL+LET)versus placebo plus letrozole(PBO+LET)in women with estrogen receptor–positive", human epidermal growth factor receptor 2–negative advanced breast cancer(ER+, J Clin Oncol, pp.2022, 40(17 Suppl)[DOI]
  25. Hortobagyi GN, "Overall survival with ribociclib plus letrozole in advanced breast cancer", N Engl J Med, 386, pp.942~950 (2022)
  26. Sledge GW Jr, "The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2 : a randomized clinical trial", JAMA Oncol, 6, pp.116~124 (2020)
  27. Goetz MP, "MONARCH 3 : abemaciclib as initial therapy for advanced breast cancer", J Clin Oncol, 35, pp.3638~3646 (2017)
  28. Slamon DJ, "Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer : MONALEESA-3", J Clin Oncol, 36, pp.2465~2472 (2018)
  29. Gradishar WJ, "Breast cancer, version 3. 2020, NCCN clinical practice guidelines in oncology", J Natl Compr Canc Netw, 18, pp.452~478 (2020)
  30. Lu YS, "Abstract GS1-10: primary results from the randomized phase II RIGHT choice trial of premenopausal patients with aggressive HR+", HER2− advanced breast cancer treated with ribociclib+endocrine therapy vs. physician’s choice combination chemotherapy, 2023, pp.83(5 Suppl), GS1~GS10
  31. McAndrew NP, "Clinical review on the management of hormone receptor-positive metastatic breast cancer", JCO Oncol Pract, 18, pp.319~327 (2022)
  32. Spring LM, "Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4", 6 inhibitors in breast cancer : practical considerations and recommendations, 2017, pp.22, 1039~1048
  33. Thill M, "Management of adverse events during cyclin-dependent kinase 4", 6(CDK4, Ther Adv Med Oncol, pp.2018, 10[DOI]
  34. Llombart-Cussac A, "Fulvestrant-palbociclib vs. letrozole-palbociclib as initial therapy for endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer : a randomized clinical trial", JAMA Oncol, 7, pp.1791~1799 (2021)
  35. Turner NC, "Overall survival with palbociclib and fulvestrant in advanced breast cancer", N Engl J Med, 379, pp.1926~1936 (2018)
  36. Cardoso F, "ESO-ESMO 2nd international consensus guidelines for advanced breast cancer(ABC2)", Breast, 23, pp.489~502 (2014)
  37. Llombart-Cussac A, "Abstract PD13-11 : PD13-11 final overall survival analysis of Monarch 2 : a phase 3 trial of abemaciclib plus fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer", Cancer Res, 83(5 Suppl), pp.PD13~11 (2023)
  38. Slamon DJ, "Overall survival with ribociclib plus fulvestrant in advanced breast cancer", N Engl J Med, 382, pp.514~524 (2020)
  39. Dickler MN, "MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR(+)", HER2(-)metastatic breast cancer, 2017, pp.23, 5218~5224
  40. Hamilton E, "nextMONARCH : abemaciclib monotherapy or combined with tamoxifen for metastatic breast cancer", Clin Breast Cancer, 21, pp.181~190 (2021)
  41. Elliott MJ, "Development of novel agents for the treatment of early estrogen receptor positive breast cancer", Breast, 62(Suppl 1), pp.S34~42 (2022)
  42. Cancer Genome Atlas Network, "Comprehensive molecular portraits of human breast tumours", Nature, 490, pp.61~70 (2012)
  43. Andre F, "Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer", N Engl J Med, 380, pp.1929~1940 (2019)
  44. Rugo HS, "Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4", 6 inhibitor(BYLieve) : one cohort of a phase 2, multicentre, open-label, non-comparative study, 2021, pp.22, 489~498
  45. Jones RH, "Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer(FAKTION) : a multicentre, randomised, controlled, phase 2 trial", Lancet Oncol, 21, pp.345~357 (2020)
  46. Howell SJ, "Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer(FAKTION) : overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial", Lancet Oncol, 23, pp.851~864 (2022)
  47. Turner NC, "Capivasertib in hormone receptor-positive advanced breast cancer", N Engl J Med, 388, pp.2058~2070 (2023)
  48. Baselga J, "Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer", N Engl J Med, 366, pp.520~529 (2012)
  49. Yardley DA, "Everolimus plus exemestane in postmenopausal patients with HR(+)breast cancer : BOLERO-2 final progression-free survival analysis", Adv Ther, 30, pp.870~884 (2013)
  50. Piccart M, "Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer : overall survival results from BOLERO-2dagger", Ann Oncol, 25, pp.2357~2362 (2014)
  51. Chandarlapaty S, "Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer : a secondary analysis of the BOLERO-2 clinical trial", JAMA Oncol, 2, pp.1310~1315 (2016)
  52. Bidard FC, "Elacestrant(oral selective estrogen receptor degrader)versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer : results from the randomi-zed phase III EMERALD trial", J Clin Oncol, 40, pp.3246~3256 (2022)
  53. Corti C, "Novel endocrine therapies : what is next in estrogen receptor positive, HER2 negative breast cancer?", Cancer Treat Rev, 117, pp.102569~ (2023)
  54. Oliveira M, "Abstract GS3-02: GS3-02 camizestrant, a next generation oral SERD vs. fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: results of the randomized, multi-dose phase 2 SERENA-2 trial", Cancer Res, 83(5 Suppl), pp.GS3~02 (2023)
  55. Im SA, "SERENA-4 : a phase 3 comparison of AZD9833(camizestrant)plus palbociclib, versus anastrozole plus pal-bociclib, for patients with ER-positive, HER2-negative advan-ced breast cancer who have not previously received systemic treatment for advanced disease", J Clin Oncol, 39(15 Suppl), pp.TPS1101~ (2021)
  56. Bidard FC, "Abstract OT2-11-05 : SERENA-6 : a phase III study to assess the efficacy and safety of AZD9833(camizestrant)compared with aromatase inhibitors when given in combination with palbociclib or abemaciclib in patients with HR+", HER2-metastatic breast cancer with detectable ESR1m who have not experienced disease progression on first-line therapy, 2022, pp.82(4 Suppl), OT2-11-05~
  57. Jimenez MM, "211MO Giredestrant(GDC-9545)vs. physician choice of endocrine monotherapy(PCET)in patients(pts)with ER+, HER2– locally advanced", metastatic breast cancer(LA, Ann Oncol, pp.2022, 33(Suppl 7)[DOI]
  58. Patel R, "An emerging generation of endocrine therapies in breast cancer : a clinical perspective", NPJ Breast Cancer, 9, pp.20~ (2023)
  59. Ferraro E, "Acce-lerating drug development in breast cancer : new frontiers for ER inhibition", Cancer Treat Rev, 109, pp.102432~ (2022)
  60. Prakash R, "Homologous recombination and human health : the roles of BRCA1, BRCA2, and associated proteins", Cold Spring Harb Perspect Biol, 7, pp.a016600~ (2015)
  61. Turk AA, "PARP inhibitors in breast cancer : bringing synthetic lethality to the bedside", Cancer, 124, pp.2498~2506 (2018)
  62. Alsop K, "BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer : a report from the Australian Ovarian Cancer Study Group", J Clin Oncol, 30, pp.2654~2663 (2012)
  63. Robson M, "Olaparib for metastatic breast cancer in patients with a germline BRCA mutation", N Engl J Med, 377, pp.523~533 (2017)
  64. Robson ME, "OlympiAD final overall survival and tolerability results : olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer", Ann Oncol, 30, pp.558~566 (2019)
  65. Litton JK, "Talazoparib in patients with advanced breast cancer and a germline BRCA mutation", N Engl J Med, 379, pp.753~763 (2018)
  66. Zhang H, "HER2-low breast cancers", Am J Clin Pathol, 157, pp.328~336 (2022)
  67. Ogitani Y, "Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity", Cancer Sci, 107, pp.1039~1046 (2016)
  68. Modi S, "Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer : results from a phase Ib study", J Clin Oncol, 38, pp.1887~1896 (2020)
  69. Modi S, "Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer", N Engl J Med, 387, pp.9~20 (2022)
  70. Liu X, "Advances in Trop2-targeted therapy : novel agents and opportunities beyond breast cancer", Pharmacol Ther, 239, pp.108296~ (2022)
  71. Kalinsky K, "Sacituzumab govitecan in previously treated hormone receptor-positive", HER2-negative metastatic breast cancer : final results from a phase I, Ann Oncol, pp.2020, 31[DOI]
  72. Rugo HS, "Primary results from TROPiCS-02 : a randomized phase 3 study of sacituzumab govitecan(SG)versus treatment of physician’s choice(TPC)in patients(Pts)with hormone receptor–positive", HER2-negative(HR+, J Clin Oncol, pp.2022, 40(17 Suppl)[DOI]
  73. Rugo HS, "Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer(TROPiCS-02) : a randomised, open-label, multicentre, phase 3 trial", Lancet (2023)[DOI]
  74. Rugo HS, "Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive", human epidermal growth factor receptor 2-negative advanced breast cancer, 2018, pp.24, 2804~2811
  75. Chaudhuri S, "Immunotherapy in breast cancer : a clinician’s perspective", J Natl Cancer Cent, 1, pp.47~57 (2021)
  76. Tolaney SM, "Effect of eribulin with or without pembrolizumab on progression-free survival for patients with hormone receptor-positive, ERBB2-negative metastatic breast cancer : a randomized clinical trial", JAMA Oncol, 6, pp.1598~1605 (2020)
  77. Shah AN, "Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer", J Immunother Cancer, 8, pp.e000173~ (2020)
  78. Perez-Garcia JM, "Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, loca-lly recurrent or metastatic breast cancer(KELLY) : an open-label, multicentre, single-arm, phase Ⅱ trial", Eur J Cancer, 148, pp.382~394 (2021)
  79. Kim SH, "A phase IB", II study of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer(KCSG BR18-16), 2022, pp.40(16 Suppl), 1098~
  80. Rugo HS, "KEYNOTE-B49 : a phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+", HER2-locally recurrent inoperable or metastatic breast cancer, 2022, pp.40(16 Suppl), TPS1118~
  81. Yuan Y, "Phase I", II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer, 2021, pp.154, 11~20

관련 논문AI추천

Targeting CDK4/6 in breast cancerArmand Jessica, Shanabag Anusha, Son Eugene, Yang Hee Won생화학분자생물학회 · Experimental and Molecular Medicine2025 · 제57권 Comparison of the Efficacy between First-Line Treatment Regimens for Patients with Hormone Receptor-Positive and HER2-Negative Metastatic Breast CancerChan Sub Park, Hyun-Ah Kim, In-Chul Park, Ji Yea Kim, Juhyeon Lee, Kwang Hyun Choi, Min Ki Seong, Na Won Kim, Sang Hee Kim, Woo Chul Noh한국유방암학회 · Journal of Breast Disease2021 · 제9권 제2호메타분석을 이용한 호르몬 수용체 양성/인체 상피세포 성장 인자 수용체 음성 진행성 유방암에서 사이클린 의존성 인산화효소 4/6 억제제와 방향화효소 억제제 병용요법과 방향화효소 억제제 단독요법의 임상적 유효성 및 안전성 비교 연구김경, 김민지, 백인환, 손기호, 조문경한국임상약학회 · 한국임상약학회지2020 · 제30권 제1호유방암의 호르몬 치료이수이대한내과학회 · 대한내과학회지2023 · 제98권 제6호Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer김성배, 김정은, 안진희, 정경해, 정재호, 정혜현대한암학회 · Cancer Research and Treatment2022 · 제54권 제2호Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL)강석윤, 김건민, 김지현, 박연희, 박인해, 안희경, 이지윤, 임석아, 정경해대한암학회 · Cancer Research and Treatment2021 · 제53권 제3호

이 간행물의 다른 논문 (30건)

Barriers in Oligometastasis Care in Korea: Radiation Oncologists’ Perspectives안용찬, 지의규, 조원경, 임채홍pp. 1063-1064Establishment of Patient-Derived Organoids Using Ascitic or Pleural Fluid from Cancer Patients김윤희, 이우진, 공선영, 채희정, 심효은, 심성훈, 이근석, 우상명, 천정원, 최원영, 유예빈, 이미림pp. 1077-1086Clinicopathological Characteristics of NRG1 Fusion-Positive Solid Tumors in Korean Patients주비오, 이청, 김경아, 이충근, 심효섭, 차윤진pp. 1087-1095A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy권정혜, 안희경, 하주영, 김호영, 손주혁, 강진형, 김찬규, 김지연, 오소연, 이경희, 고수진, 구동회, 이대원, 지준호, 강정훈, 오성용, 김성배, 맹치훈, 이근석, 원영웅pp. 1096-1103Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma정현애, 박근칠, 박세훈, 오동렬, 안용찬, 안명주, 이세훈, 김하나pp. 1104-1112
원문 보기